Related Experiment Videos
Evaluation of humoral response to tumor antigens using recombinant expression-based serological mini-arrays (SMARTA)
Maria A Lagarkova1, Ekaterina P Koroleva, Dmitry V Kuprash
1Department of Molecular Immunology, Belozersky Institute of Physico-Chemical Biology, Center for Molecular Medicine, Moscow State University, Vorobjovy Gory, 119899, Moscow, Russia.
Abstract:
Screening of expression cDNA libraries derived from human neoplasms with autologous sera (SEREX) is an established method for defining antigens immunogenic in individual cancer patients. Although the majority of SEREX-derived cDNA clones encode autoantigens, some of them represent shared cancer antigens with cancer-related serological profiles. Routine evaluation of multiple SEREX-derived clones in serological assays using panels of allogeneic sera from cancer patients is an important step towards defining disease parameters of diagnostic and prognostic significance. Here we show how the seroreactivity of multiple SEREX-derived antigens can be simultaneously evaluated using a rapid semi-quantitative protocol of allogeneic screening, which we call SMARTA (serological mini-arrays of recombinant tumor antigens).
Insights
We developed SMARTA, a novel method for simultaneously evaluating multiple cancer antigens identified through SEREX (serological analysis of recombinant tumor antigens). This technique aids in defining cancer-specific antigens for improved diagnostics and prognostics.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Serological analysis of recombinant tumor antigens (SEREX) identifies cancer antigens from patient sera.
- While many SEREX antigens are patient-specific autoantigens, some shared tumor antigens offer diagnostic and prognostic potential.
- Evaluating multiple SEREX antigens requires efficient serological screening methods.
Purpose of the Study:
- To introduce a rapid, semi-quantitative method for simultaneous evaluation of multiple SEREX-derived antigens.
- To facilitate the identification of shared cancer antigens with diagnostic and prognostic significance.
- To advance the field of cancer biomarker discovery through improved serological screening.
Main Methods:
- Development of a novel protocol named SMARTA (serological mini-arrays of recombinant tumor antigens).
- SMARTA enables the simultaneous assessment of seroreactivity against multiple SEREX-derived antigens.
- Utilizes allogeneic serum panels from cancer patients for high-throughput screening.
Main Results:
- Demonstrated the feasibility of simultaneously evaluating the seroreactivity of numerous SEREX antigens.
- Established a rapid and semi-quantitative approach for allogeneic screening.
- Provided a foundation for identifying shared cancer antigens with clinical relevance.
Conclusions:
- SMARTA offers an efficient strategy for analyzing multiple tumor antigens.
- This method can accelerate the discovery of cancer biomarkers for diagnosis and prognosis.
- The technique holds promise for advancing personalized cancer medicine.